CymBay Therapeutics, Inc. (NASDAQ: CBAY) is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. The company’s portfolio includes arhalofenate, which has shown two therapeutic actions in a single drug in multiple phase II gout studies; and MBX-8025, a potent, selective, orally active PPARδ agonist. A phase II study of MBX-8025 in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. CymaBay has two ongoing clinical studies for MBX-8025. For more information, visit the company’s website at www.cymabay.com